Star Combo Pharma Ltd.

As of June 30, 2024, Star Combo Pharma Ltd. carries a market capitalization of 14.86M, placing it among publicly traded companies globally. Its enterprise value stands at 11.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Star Combo Pharma Ltd. has 135.08M shares outstanding.

As of June 30, 2024, Star Combo Pharma Ltd. trades at a trailing price-to-earnings ratio of 19.88. The price-to-sales ratio is 0.57, and the price-to-book ratio stands at 0.45.

As of June 30, 2024, Star Combo Pharma Ltd. trades at an EV/EBITDA multiple of 7.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 11.72M versus a market cap of 14.86M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Star Combo Pharma Ltd. maintains a current ratio of 3.72, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.02, indicating elevated leverage, while an interest coverage ratio of 7.61 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Star Combo Pharma Ltd. posted a return on equity (ROE) of 2.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.19, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.38, useful for judging operating efficiency across full business cycles. Inventory turnover of 3.53 indicates how many times Star Combo Pharma Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, Star Combo Pharma Ltd. recorded 253,731.00 in income tax expense. That works out to an effective tax rate of 25.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.00M, leaving 747,330.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 21, 2026, Star Combo Pharma Ltd.'s stock has declined approximately 30.00% over the past 52 weeks. The 50-day moving average sits at 0.13, while the 200-day moving average is 0.19.

Over the twelve months ended June 30, 2024, Star Combo Pharma Ltd. generated 26.02M in revenue and converted that into 747,330.00 in net income, yielding earnings per share of 0.01. EBITDA reached 1.49M, while operating income came in at -96,377.00.

As of June 30, 2024, Star Combo Pharma Ltd. holds 7.36M in cash and equivalents against 4.03M in total debt, resulting in a net debt position of -7.35M. Total book value stands at 33.32M, with working capital of 13.26M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Star Combo Pharma Ltd. posted a gross margin of 28.47, reflecting its pricing power and cost economics. The operating margin of -0.37 and net profit margin of 2.87 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield reaches 2.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Star Combo Pharma Ltd. shareholders.

As of June 30, 2024, Star Combo Pharma Ltd. has an Altman Z-Score of 1.61, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.